Share ownership Sana Biotechnology, Inc.

SANA

US7995661045

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:24:25 11/06/2026 BST			5-day change	1st Jan Change
2.835 ^USD	+0.53%		-4.05%	-30.22%

06-10	Sana Biotechnology, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 04:00 PM
05-15	Sana Biotechnology Raises $69 Million Through ATM Equity Offering	MT

Share class: Sana Biotechnology, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	278,291,590	260,181,861 ( 93.49 %)	0	93.49 %

Major shareholders: Sana Biotechnology, Inc.

Name	Stocks	%	Valuation
ARCH Venture Partners LLC 17.73 %	45,860,681	17.73 %	151 M $
Fidelity Management & Research Co. LLC 14.47 %	37,430,284	14.47 %	124 M $
Flagship Pioneering, LLC 9.664 %	25,001,856	9.664 %	83 M $
RA Capital Management LP 7.248 %	18,750,000	7.248 %	62 M $
BlackRock Advisors LLC 5.142 %	13,301,475	5.142 %	44 M $
STATE STREET CORPORATION 4.073 %	10,538,086	4.073 %	35 M $
Canada Pension Plan Investment Board 3.951 %	10,221,900	3.951 %	34 M $
Steven Harr 3.464 %	8,960,751	3.464 %	30 M $
Vanguard Capital Management LLC 2.874 %	7,434,724	2.874 %	25 M $
Baillie Gifford & Co. 2.555 %	6,609,065	2.555 %	22 M $
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	82.28%
Individuals	7.01%
State Street Corp.	4.07%
Others	2.83%
Alphabet, Inc.	1.09%
Schweizerische Nationalbank	0.13%
Banque Cantonale Vaudoise	0.04%
Manulife Financial Corp.	0.03%
SEI Investments Co.	0.01%
Unknown	2.51%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	80.49%
Individuals	7.01%
United Kingdom	5.24%
Canada	4%
Switzerland	0.32%
Ireland	0.17%
Luxembourg	0.12%
Cayman Islands	0.04%
France	0.04%
China	0.04%
Norway	0.01%
South Korea	0.01%

Based on 1000 largest holdings

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), oncology, and B cell mediated autoimmune diseases. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline products include SC451 and UP421. SC451 is its HIP-edited product candidate for the treatment of type 1 diabetes. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. Its ex vivo cell engineering platform is focused on engineering hypoimmune cells that engraft, function, and persist in patients by evading immune rejection.

Employees

142

Sector

Biotechnology & Medical Research

More about the company